Generic placeholder image

Current Respiratory Medicine Reviews

Author(s): Alam Nawaz, Manel Arjun Nayak*, Samarth Mahadevappa and Ashwin Kamath

DOI: 10.2174/1573398X16999200406140921

DownloadDownload PDF Flyer Cite As
Association of the Clinico-Demographic and Laboratory Profile with Treatment Outcomes in Patients with Drug-Resistant Pulmonary Tuberculosis

Page: [39 - 46] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: Drug-resistant tuberculosis (DR-TB) is a significant public health problem, especially in the developing and underdeveloped countries; its treatment is relatively expensive, of longer duration, and associated with more adverse effects.

Objective: The objective of this study was to report the treatment outcomes in patients with DR-TB and determine if a few selected clinico-demographic parameters and baseline laboratory values, done as part of the pre-treatment evaluation, have any impact on sputum culture conversion and outcomes. The aim was to identify the potential factors associated with unfavourable outcomes prior to starting the treatment.

Methods: A retrospective analysis of data of patients diagnosed with DR-TB admitted at our centre from January 2015 to May 2016 was done. Of the 114 patients included, culture reports were available in 85 and 72 patients at the end of the third and sixth month, respectively. The clinicodemographic and laboratory parameters were compared with the sputum culture report at the end of the third and sixth month and final treatment outcomes.

Results: Favorable outcome (cured) was seen in 33.3% (38/114) patients. Female gender was associated with delayed sputum culture conversion at three months (P = 0.020). A positive culture at the end of the sixth month was significantly associated with unfavourable outcomes (P = 0.002). A low body mass index (BMI) (15.86 [IQR, 14.10-18.11]) and a higher platelet count (358 × 109/L [IQR, 282-4.85]) at the initiation of treatment were independently and significantly associated with unfavorable outcomes.

Conclusion: Patients with a low BMI and high platelet count are more likely to have unfavourable treatment outcomes. Identifying patients with these risk factors during the pre-treatment phase, more intensive follow-up during the treatment course could be advocated.

Keywords: Body mass index, drug-resistant tuberculosis, laboratory profile, platelet count, treatment outcome, clinicodemographic parameters.

Graphical Abstract

[1]
Report of the first national anti-tuberculosis drug resistance survey India 2016.Available from: https://tbcindia.gov.in/showfile. php?lid=3315
[2]
Singla R, Sarin R, Khalid UK, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis 2009; 13(8): 976-81.
[PMID: 19723377]
[3]
Parmar MM, Sachdeva KS, Dewan PK, et al. Unacceptable treatment outcomes and associated factors among India’s initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement. PLoS One 2018; 13(4), e0193903
[http://dx.doi.org/10.1371/journal.pone.0193903] [PMID: 29641576]
[4]
Subhash HS, Ashwin I, Jesudason MV, et al. Clinical characteristics and treatment response among patients with multidrug-resistant tuberculosis: a retrospective study. Indian J Chest Dis Allied Sci 2003; 45(2): 97-103.
[PMID: 12715931]
[5]
Udwadia ZF, Moharil G. Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai. Lung India 2014; 31(4): 336-41.
[http://dx.doi.org/10.4103/0970-2113.142101] [PMID: 25378840]
[6]
Joseph P, Desai VB, Mohan NS, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011; 133(5): 529-34.
[PMID: 21623039]
[7]
Dhingra VK, Rajpal S, Mittal A, Hanif M. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc 2008; 55(1): 15-21.
[PMID: 18361306]
[8]
Dole SS, Waghmare VN, Shaikh AM. Clinical profile and treatment outcome of drug resistant tuberculosis patients of western Maharashtra, India. J Assoc Physicians India 2017; 65(12): 18-21.
[PMID: 31556267]
[9]
Arora VK, Sarin R, Singla R, et al. DOTS-Plus for patients with multidrug-resistant tuberculosis in India: early results after three years. Indian J Chest Dis Allied Sci 2007; 49: 75-9.
[10]
Prasad R, Verma SK, Sahai S, Kumar S, Jain A. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci 2006; 48(3): 183-6.
[PMID: 18610675]
[11]
Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J 2017; 49(1), 1601075
[http://dx.doi.org/10.1183/13993003.01075-2016] [PMID: 28100546]
[12]
Sharma SK, Kohli M, Yadav RN, et al. Evaluating the diagnostic Accuracy of expert MTB/RIF assay in pulmonary tuberculosis. PLoS One 2015; 10(10), e0141011
[http://dx.doi.org/10.1371/journal.pone.0141011] [PMID: 26496123]
[13]
Guidelines on programmatic management of drug resistant TB (PMDT) in India 2012.Available from: https://tbcindia.gov.in/WriteReadData/l892s/8320929355Guidelines%20for%20PMDT%20in%20India%20-%20May%202012.pdf
[14]
Putri FA, Burhan E, Nawas A, et al. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia. Int J Tuberc Lung Dis 2014; 18(5): 564-70.
[http://dx.doi.org/10.5588/ijtld.13.0602] [PMID: 24903794]
[15]
Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty 2017; 6(1): 7.
[http://dx.doi.org/10.1186/s40249-016-0214-x] [PMID: 28093078]
[16]
Casha AR, Scarci M. The link between tuberculosis and body mass index. J Thorac Dis 2017; 9(3): E301-3.
[http://dx.doi.org/10.21037/jtd.2017.03.47] [PMID: 28449528]
[17]
Yen YF, Chuang PH, Yen MY, et al. Association of body mass index with tuberculosis mortality: a population-based follow-up study. Medicine (Baltimore) 2016; 95(1), e2300
[http://dx.doi.org/10.1097/MD.0000000000002300] [PMID: 26735532]
[18]
Lai HH, Lai YJ, Yen YF. Association of body mass index with timing of death during tuberculosis treatment. PLoS One 2017; 12(1), e0170104
[http://dx.doi.org/10.1371/journal.pone.0170104] [PMID: 28085951]
[19]
Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 2004; 8(3): 286-98.
[PMID: 15139466]
[20]
Raja A. Immunology of tuberculosis. Indian J Med Res 2004; 120(4): 213-32.
[PMID: 15520479]
[21]
Schaible UE, Kaufmann SH. Malnutrition and infection: complex mechanisms and global impacts. PLoS Med 2007; 4(5), e115
[http://dx.doi.org/10.1371/journal.pmed.0040115] [PMID: 17472433]
[22]
Chandrasekaran P, Saravanan N, Bethunaickan R, Tripathy S. Malnutrition: Modulator of immune responses in tuberculosis. Front Immunol 2017; 8: 1316.
[http://dx.doi.org/10.3389/fimmu.2017.01316] [PMID: 29093710]
[23]
Ali RA, Wuescher LM, Worth RG. Platelets: essential components of the immune system. Curr Trends Immunol 2015; 16: 65-78.
[PMID: 27818580]
[24]
Renshaw AA, Gould EW. Thrombocytosis is associated with Mycobacterium tuberculosis infection and positive acid-fast stains in granulomas. Am J Clin Pathol 2013; 139(5): 584-6.
[http://dx.doi.org/10.1309/AJCPCM1CKASVBMBP] [PMID: 23596109]
[25]
Şahin F, Yazar E, Yıldız P. Prominent features of platelet count, plateletcrit, mean platelet volume and platelet distribution width in pulmonary tuberculosis. Multidiscip Respir Med 2012; 7(1): 38.
[http://dx.doi.org/10.1186/2049-6958-7-38] [PMID: 23114411]
[26]
Mirsaeidi M, Peyrani P, Aliberti S, et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest 2010; 137(2): 416-20.
[http://dx.doi.org/10.1378/chest.09-0998] [PMID: 19837825]
[27]
Hollen CW, Henthorn J, Koziol JA, Burstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol 1991; 79(2): 286-90.
[http://dx.doi.org/10.1111/j.1365-2141.1991.tb04534.x] [PMID: 1958487]
[28]
Singh PP, Goyal A. Interleukin-6: a potent biomarker of mycobacterial infection. Springerplus 2013; 2: 686.
[http://dx.doi.org/10.1186/2193-1801-2-686] [PMID: 24455461]
[29]
Martinez AN, Mehra S, Kaushal D. Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection. J Infect Dis 2013; 207(8): 1253-61.
[http://dx.doi.org/10.1093/infdis/jit037] [PMID: 23359591]
[30]
VanHeyningen TK, Collins HL, Russell DG. IL-6 produced by macrophages infected with Mycobacterium species suppresses T cell responses. J Immunol 1997; 158(1): 330-7.
[PMID: 8977207]
[31]
Kang YA, Kim SY, Jo KW, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration 2013; 86(6): 472-8.
[http://dx.doi.org/10.1159/000348374] [PMID: 23689646]
[32]
Isaakidis P, Das M, Kumar AM, et al. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India. PLoS One 2014; 9(10), e110461
[http://dx.doi.org/10.1371/journal.pone.0110461] [PMID: 25333696]